Pulmonary hypertension (PH) is a progressive cardiovascular disorder characterized by elevated pulmonary arterial pressure and right ventricular dysfunction, leading to significant morbidity and mortality. Phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil and tadalafil, have emerged as effective therapeutic agents in PH management, often used either as first-line or adjunct therapy. While their clinical efficacy is well-documented, the economic implications and cost-effectiveness of PDE-5 inhibitors compared to standard therapies, including endothelin receptor antagonists and prostacyclin analogs, remain underexplored.

This study aims to evaluate the pharmacoeconomic profile of PDE-5 inhibitors versus standard PH therapy by analyzing direct medical costs, hospitalization rates, quality-adjusted life years (QALYs), and adverse event profiles. Data were collected from clinical trials, observational studies, and real-world patient cohorts, and cost-effectiveness ratios were calculated using a health-economic model over a 12-month treatment period.

Results indicate that PDE-5 inhibitors provide comparable or superior clinical outcomes with lower overall healthcare costs, primarily due to reduced hospitalization and administration costs. Adverse event profiles were manageable, supporting long-term use. The cost per QALY gained with PDE-5 inhibitors was significantly lower than that of standard therapies, highlighting their potential as a cost-effective strategy for PH management.